Lenalidomide for the treatment of B-cell malignancies.

  title={Lenalidomide for the treatment of B-cell malignancies.},
  author={Asher Alban Chanan-Khan and Bruce D Cheson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={26 9},
Lenalidomide is a novel anticancer agent that has made a major impact in the treatment of patients with B-cell malignancies. A more potent analog of thalidomide, lenalidomide was developed to enhance immunomodulatory properties with improved safety profile. Its antitumor activity seems mediated through modulation of both the cytokine and cellular tumor cell microenvironment. Preclinical as well as clinical observations demonstrate that lenalidomide downregulates production of various critical… CONTINUE READING